For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Obtains Approval in Japan for Supplementary Indication for “Artist® Tablets”

Tokyo, Japan (August 24, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has obtained approval in Japan for a supplementary indication of “tachycardiac atrial fibrillation” for Artist® Tablets 2.5mg, 10mg and 20mg (generic name: Carvedilol) for the treatment of hypertension, angina, and chronic heart failure.

 

Artist^® features alpha-blocking action alongside nonselective beta-blocking with vasodilation action, and based on the beta-blocking effect, a lowering of the heart rate is shown. In both Japanese and international guidelines, heart rate control therapy is recommended for atrial fibrillation patients.

 

As a result of requests received from atrial fibrillation-related medical societies, Daiichi Sankyo conducted Phase 3 clinical trials in Japan and obtained supplementary approval for Artist® Tablets for the aforementioned indication.

 

Daiichi Sankyo aims to contribute further in the field of medicine by providing a new option through this drug to patients and medical professionals involved in the treatment of atrial fibrillation, as well as by continuing to expand its product lineup.